GRAIL, Inc. (GRAL): Results of Operations and Financial Condition
GRAIL, Inc. (GRAL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex9912026q2earningspressre.htm EX-99.1 Document NEWS RELEASE Exhibit 99.1 GRAIL Reports Second Quarter 2026 Financial Results Q2 Galleri ® Test Volume Increased 35% to More Than 61,000 Year-Over-Year, and Galleri Revenue Grew 24% to $42.6 Million Galleri Test Volume and
How this was made
The 30-second read
Why it matters
The quarter adds new datapoints on Galleri adoption (test volume and revenue growth), liquidity (cash and short-term marketable securities), and a specific upcoming regulatory process (FDA advisory committee in fall) tied to its PMA submission.
Market read
Traders get a fresh quarterly snapshot plus a near-term catalyst window for FDA advisory committee review, which can reprice regulatory and commercialization expectations.
What to watch
The article emphasizes ASCO presentations and PMA support, but does not quantify probability of advisory committee outcomes or provide updated guidance, so traders may need to wait for FDA-related updates for conviction.
Background
GRAIL filed an 8-K (Item 2.02) with its Q2 2026 results and accompanying earnings release (Exhibit 99.1).
Ticker impact
GRAIL reported Q2 2026 revenue of $44.7M, Galleri test revenue of $42.6M, and $861.6M cash, plus an FDA advisory committee expected in fall.
Near-term bias modestly positive on revenue/test-volume growth and cash position, with volatility around the upcoming FDA advisory committee expectations.
This is a primary 8-K with new quarterly results and explicit regulatory timing, but it does not include FDA decision outcomes or guidance changes beyond the advisory committee expectation.
Market effects
Reinforces investor focus on clinical validation and commercial scaling for multi-cancer early detection (MCED) platforms.
Samsung collaboration points to potential future Asia commercialization optionality, subject to regulatory approvals.
Highlights continued capital formation and regulatory progression for next-generation oncology diagnostics.
Counterpoint
Despite growth in test volume and revenue, adjusted EBITDA loss widened and net loss remains very large, so the market may still discount the quarter until regulatory milestones translate into approvals and sustained profitability.
Key entities
- issuerGRAIL, Inc.
Nasdaq-listed company reporting Q2 2026 financial results and providing an FDA advisory committee timing expectation.
- partnerSamsung C&T Corporation and Samsung Electronics Co., Ltd.
Completed a $110M equity financing and plan to collaborate on commercializing Galleri in South Korea.
- partnerPriority Health
Collaboration to make Galleri available to self-insured employer groups in Michigan.
- regulatorU.S. Food and Drug Administration (FDA)
Expected to hold an advisory committee in the fall to review GRAIL’s Galleri PMA application.
